DE602004008098T8 - Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren - Google Patents

Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren Download PDF

Info

Publication number: DE602004008098T8
Authority: DE; Germany
Prior art keywords: pyrazines; gsk; triazolo; inhibitors; substituted
Prior art date: 2003-10-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

DE602004008098T

Other languages

English (en)

Other versions

DE602004008098T2 (de

DE602004008098D1 (de

Inventor

John W. c/o Pfizer G Groton BENBOW

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Products Inc

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-10

Filing date

2004-09-27

Publication date

2008-04-17

2004-09-27 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

2007-09-20 Publication of DE602004008098D1 publication Critical patent/DE602004008098D1/de

2007-12-13 Publication of DE602004008098T2 publication Critical patent/DE602004008098T2/de

2008-04-17 Application granted granted Critical

2008-04-17 Publication of DE602004008098T8 publication Critical patent/DE602004008098T8/de

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE602004008098T 2003-10-10 2004-09-27 Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren Active DE602004008098T8 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US51022403P	2003-10-10	2003-10-10
US510224P		2003-10-10
PCT/IB2004/003137 WO2005035532A1 (en)	2003-10-10	2004-09-27	Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors

Publications (3)

Publication Number	Publication Date
DE602004008098D1 DE602004008098D1 (de)	2007-09-20
DE602004008098T2 DE602004008098T2 (de)	2007-12-13
DE602004008098T8 true DE602004008098T8 (de)	2008-04-17

Family

ID=34435073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE602004008098T Active DE602004008098T8 (de)	2003-10-10	2004-09-27	Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren

Country Status (10)

Country	Link
US (1)	US7709473B2 (de)
EP (1)	EP1678180B1 (de)
JP (1)	JP2007508290A (de)
AT (1)	ATE369370T1 (de)
BR (1)	BRPI0415185A (de)
CA (1)	CA2541832C (de)
DE (1)	DE602004008098T8 (de)
ES (1)	ES2288270T3 (de)
MX (1)	MXPA06004043A (de)
WO (1)	WO2005035532A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602004024814D1 (de)	2003-11-04	2010-02-04	Merck & Co Inc	Substituierte naphthyridinonderivate
EP2258359A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US7678363B2 (en)	2005-08-26	2010-03-16	Braincells Inc	Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
DE102007012645A1 (de) *	2007-03-16	2008-09-18	Bayer Healthcare Ag	Substituierte Imidazo- und Triazolopyrimidine
DE102007032349A1 (de) *	2007-07-11	2009-01-15	Bayer Healthcare Ag	Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
WO2009017453A1 (en) *	2007-07-30	2009-02-05	Astrazeneca Ab	New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
PE20091074A1 (es) *	2007-12-13	2009-07-26	Bayer Healthcare Ag	Triazolotriazinas y triazolopirazinas y su uso
DE102008023801A1 (de)	2008-05-15	2009-11-19	Bayer Schering Pharma Aktiengesellschaft	Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
JP5559604B2 (ja) *	2009-05-27	2014-07-23	富山化学工業株式会社	３，６−ジクロロ−２−ピラジンカルボニトリルの製造法
US9073927B2 (en)	2010-01-22	2015-07-07	Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii	Inhibitors of PI3 kinase
WO2011141713A1 (en)	2010-05-13	2011-11-17	Centro Nacional De Investigaciones Oncologicas (Cnio)	New bicyclic compounds as pi3-k and mtor inhibitors
KR102087313B1 (ko)	2010-08-10	2020-03-11	렘펙스 파머수티클스 인코퍼레이티드	고리형 보론산 에스터 유도체의 제조방법
WO2013033461A1 (en)	2011-08-31	2013-03-07	Rempex Pharmaceuticals, Inc.	Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9156858B2 (en)	2012-05-23	2015-10-13	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en)	2012-06-06	2020-02-18	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103121970B (zh) *	2012-12-04	2015-04-29	中国科学院昆明植物研究所	苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
CN103121969A (zh) *	2012-12-04	2013-05-29	中国科学院昆明植物研究所	苯并咪唑及其衍生物，其药物组合物及其应用
US9101638B2 (en)	2013-01-04	2015-08-11	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
MX2015008627A (es)	2013-01-04	2015-09-23	Rempex Pharmaceuticals Inc	Derivados de acido boronico y usos terapeuticos de los mismos.
US9241947B2 (en)	2013-01-04	2016-01-26	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
AU2014204045B2 (en)	2013-01-04	2018-10-18	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US9493442B2 (en)	2014-02-13	2016-11-15	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
ME03580B (de)	2014-02-13	2020-07-20	Incyte Corp	Cyclopropylamine als lsd1-hemmer
AU2015217073B2 (en)	2014-02-13	2019-08-22	Incyte Holdings Corporation	Cyclopropylamines as LSD1 inhibitors
US20170165230A1 (en)	2014-04-09	2017-06-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
WO2015171398A1 (en)	2014-05-05	2015-11-12	Rempex Pharmaceuticals, Inc.	Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2015171430A1 (en)	2014-05-05	2015-11-12	Rempex Pharmaceuticals, Inc.	Synthesis of boronate salts and uses thereof
EP3145936B1 (de)	2014-05-19	2020-09-30	Qpex Biopharma, Inc.	Borsäurederivate und therapeutische verwendungen davon
JP6680774B2 (ja) *	2014-06-17	2020-04-15	チアタイティエンチンファーマシューティカルグループカンパニーリミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd.	ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミドン類似体
CA2952992C (en) *	2014-06-17	2019-05-07	Cisen Pharmaceutical Co., Ltd.	Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
EA201692301A1 (ru)	2014-07-01	2017-06-30	Ремпекс Фармасьютикалз, Инк.	Производные бороновой кислоты и их терапевтическое применение
WO2016007727A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyrazines as lsd1 inhibitors
US9695167B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh)	2014-07-10	2020-03-11	美商英塞特公司	作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US10662205B2 (en)	2014-11-18	2020-05-26	Qpex Biopharma, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016149393A1 (en)	2015-03-17	2016-09-22	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
EP3277689B1 (de)	2015-04-03	2019-09-04	Incyte Corporation	Heterocyclische verbindungen als lsd1-hemmer
PE20181175A1 (es)	2015-08-12	2018-07-20	Incyte Corp	Sales de un inhibidor de lsd1
AU2017252328B2 (en)	2016-04-22	2023-02-23	Incyte Corporation	Formulations of an LSD1 inhibitor
WO2018005662A1 (en)	2016-06-30	2018-01-04	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
TWI806832B (zh)	2016-07-12	2023-07-01	美商銳新醫藥公司	作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
CN107602446B (zh) *	2016-07-12	2020-04-07	中国科学院上海药物研究所	1,4-双取代-1,2,3,6-四氢吡啶类化合物、其制备方法、药物组合物及其应用
BR112019014527A2 (pt)	2017-01-23	2020-02-27	Revolution Medicines, Inc.	Compostos de piridina como inibidores de shp2 alostéricos
EP3571199A1 (de)	2017-01-23	2019-11-27	Revolution Medicines, Inc.	Bicyclische verbindungen als allosterische shp2-inhibitoren
KR102626967B1 (ko)	2017-10-11	2024-01-18	큐펙스 바이오파마 인코포레이티드	보론산 유도체 및 이의 합성
RU2020115095A (ru)	2017-10-12	2021-11-12	Революшн Медсинз, Инк.	Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
KR20200099530A (ko)	2017-12-15	2020-08-24	레볼루션 메디슨즈, 인크.	알로스테릭 shp2 억제제로서의 다환식 화합물
WO2019156989A1 (en) *	2018-02-06	2019-08-15	Ideaya Biosciences, Inc.	COMPOUNDS AND METHODS FOR THE MODULATION OF AhR
US12016868B2 (en)	2018-04-20	2024-06-25	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
WO2024146945A1 (en)	2023-01-07	2024-07-11	Syngenta Crop Protection Ag	Novel carboxamide and sulfonamide pesticidal compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1235910A (en) *	1968-12-10	1971-06-16	Ici Ltd	Pharmaceutical compositions
FR2662163A1 (fr)	1990-05-16	1991-11-22	Lipha	Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JP2002297477A (ja) *	2001-03-28	2002-10-11	Sony Computer Entertainment Inc	配信システム及び配信方法
EP2082743A3 (de) *	2001-04-30	2010-03-03	Vertex Pharmaceuticals Incorporated	Inhibitoren von GSK-3 und Kristallstrukturen von GSK-3-beta-Protein und -Proteinkomplexen
EP1340759A1 (de) *	2002-02-28	2003-09-03	Sanofi-Synthelabo	1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyrimidin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
CA2520251A1 (en) *	2003-03-27	2004-10-07	Pfizer Products Inc.	Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines

2004
- 2004-09-27 DE DE602004008098T patent/DE602004008098T8/de active Active
- 2004-09-27 BR BRPI0415185-2A patent/BRPI0415185A/pt not_active IP Right Cessation
- 2004-09-27 AT AT04769486T patent/ATE369370T1/de not_active IP Right Cessation
- 2004-09-27 ES ES04769486T patent/ES2288270T3/es not_active Expired - Lifetime
- 2004-09-27 US US10/575,395 patent/US7709473B2/en not_active Expired - Fee Related
- 2004-09-27 WO PCT/IB2004/003137 patent/WO2005035532A1/en active IP Right Grant
- 2004-09-27 MX MXPA06004043A patent/MXPA06004043A/es not_active Application Discontinuation
- 2004-09-27 EP EP04769486A patent/EP1678180B1/de not_active Expired - Lifetime
- 2004-09-27 JP JP2006530734A patent/JP2007508290A/ja active Pending
- 2004-09-27 CA CA002541832A patent/CA2541832C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2288270T3 (es)	2008-01-01
EP1678180B1 (de)	2007-08-08
ATE369370T1 (de)	2007-08-15
BRPI0415185A (pt)	2006-11-28
JP2007508290A (ja)	2007-04-05
US7709473B2 (en)	2010-05-04
DE602004008098T2 (de)	2007-12-13
US20070249612A1 (en)	2007-10-25
WO2005035532A1 (en)	2005-04-21
DE602004008098D1 (de)	2007-09-20
CA2541832A1 (en)	2005-04-21
EP1678180A1 (de)	2006-07-12
CA2541832C (en)	2009-11-24
MXPA06004043A (es)	2006-06-28

Publication	Publication Date	Title
DE602004008098T8 (de)	2008-04-17	Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren
MXPA03005464A (es)	2004-04-20	Agentes antivirales.
ATE443063T1 (de)	2009-10-15	Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
EA200600973A1 (ru)	2006-10-27	ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2
AP1860A (en)	2008-07-02	Aryl fused azapolycyclic compounds.
EA200700902A1 (ru)	2007-10-26	3-ариламинопиридиновые производные
MXPA05012025A (es)	2006-02-03	Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
DK1678166T3 (da)	2009-11-09	Proteinkinaseinhibitorer
RS20050469A (en)	2007-11-15	Pyrrolopyrimidine derivatives
GT200100137A (es)	2002-05-16	Pro-drogas de derivados de 4-fenil-piridina.
TNSN03110A1 (en)	2005-12-23	Azaindoles.
IS6852A (is)	2003-06-18	Efnasambönd
DE50302975D1 (de)	2006-05-24	Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
SG149033A1 (en)	2009-01-29	Heterocyclic inhibitors of mek and methods of use thereof
MXPA05010293A (es)	2005-11-17	4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas.
SG151254A1 (en)	2009-04-30	Substituted morpholine and thiomorpholine derivatives
DK1689721T3 (da)	2010-09-20	Aminopyrazolderivater som GSK-3-ihibitorer
MXPA02010627A (es)	2004-05-17	Derivados de 2-acil-indol y su uso como farmaco antitumoral.
RS53428B (en)	2014-12-31	COMPOSITIONS AND ANTI-VIRUS ACTIVITY OF SUBSTITUTED AZAINDOLOXOSCETER PIPERAZINE DERIVATIVES
AU2003250471A8 (en)	2004-02-25	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
MXPA05013210A (es)	2006-03-09	Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
AP2001002188A0 (en)	2001-06-30	5HT1 antagonists for antidepressant therapy.
MXPA05009282A (es)	2005-10-05	Derivados de anilina sustituidos.
DE60107832D1 (en)	2005-01-20	Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
SG171472A1 (en)	2011-06-29	Substituted aniline derivatives

Legal Events

Date	Code	Title	Description
2008-08-28	8364	No opposition during term of opposition